Frontlight ResearchEarly access
WithdrawnNo phase
Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF
Key facts
- Who runs it
- University of Rochester
- Where
- Short Hills, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jan 2025
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Endocardial PVI
- Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI
- Record updated
- 9 November 2023
- Why it stopped
- Funding issues
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age > 18 years
- Symptomatic paroxysmal AF despite prior 1 or 2 PVI procedures within past 10 years (paroxysmal AF lasting up to 7 days before spontaneous termination)
- Eligible for referral for re-ablation based on current guidelines
- LA diameter < 6.0 cms on transthoracic echo
- Willingness to comply with post-procedural follow-up requirements and to sign informed consent
Who cannot take part
- Prior history of open heart surgery
- Prior history of pericarditis or pericardiocentesis
- Prior history of stroke/TIA/systemic embolism
- Coronary revascularization or valve surgery within 3 months
- Prior valve surgery using a mechanical prosthesis
- Women who are pregnant or plan to become pregnant during the course of the trial** Note: Women of childbearing potential must have a negative pregnancy test within 7 days prior to randomization
- Life expectancy <1 year for any medical condition
- History of non-compliance to medical therapy
- NYHA class IV congestive heart failure or LVEF < 25%
- An estimated glomerular filtration rate (eGFR) < 45mL/min/1.73m2, using the MDRD calculation
- Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to anticoagulation)
- Persistent or longstanding persistent AF (duration > 1 year)
- AF due to reversible cause e.g. hyperthyroid state
- Participation in other clinical trials that will affect the objectives of this study
- Inability or unwillingness to provide informed consent
- Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult
- Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial
Where in United States
- University of RochesterShort Hills, United States
About the trial
What the trial wants to find out
There is no current accepted and predictably effective ablative therapy for patients with recurrent paroxysmal atrial fibrillation after prior pulmonary vein isolation (PVI). This study will compare redo PVI with hybrid epicardial ablation incorporating posterior wall isolation and LAA clip, and redo PVI.
The 2 groups in the trial
- Endocardial PVIExisting treatment, for comparison
Endocardial complete PVI
- Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVITreatment being tested
Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison of Repeat Endocardial PVI Vs Epicardial Posterior Wall Isolation and LAA Clip Plus PVI for Recurrent Atrial Fibrillation After Prior PVI
- Record updated
- 9 November 2023